Reports Q4 revenue $2.41B, consensus $2.3B. “I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success,” said Thomas J. Appio, Chief Executive Officer, Bausch Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BHC:
- Bausch Health price target lowered to $14 from $16 at Jefferies
- Icahn takes stake in American Electric Power, exits position in Crown Holdings
- Bausch Health Issues Press Release on Regulatory Update
- Bausch Health Announces Board Members’ Amicable Retirement
- Bausch Health announces CABTREO topical gel availability in the U.S.
